| 弥漫性大B细胞淋巴瘤诊治进展 |
| |
| 引用本文： | 李陶,周立强. 弥漫性大B细胞淋巴瘤诊治进展[J]. 癌症进展, 2006, 4(5): 384-390 |
| |
| 作者姓名： | 李陶 周立强 |
| |
| 作者单位： | 中国医学科学院,中国协和医科大学,肿瘤医院,北京,100021 |
| |
| 摘 要： | 弥漫性大B细胞淋巴瘤(DLBCL)是目前最常见的成人非霍奇金淋巴瘤,不同亚型在临床表现、遗传学以及分子生物学等特征方面存在明显差异,所观察到的遗传学改变主要集中在BCL6,BCL2,cMYC,FAS(CD95)的突变和体细胞超突变的异常上。虽然CHOP方案化疗能够治愈部分DLBCL,但完全缓解率仅为45%~55%。强化化疗方案或干细胞移植可改善某些患者的长期生存,最突出和一致改善弥漫性大B细胞淋巴瘤的长期生存效果则是随着抗CD20单克隆抗体药物与化疗的联合应用。
|
| 关 键 词： | 弥漫性大B细胞淋巴瘤 诊断 化疗 |
Progress in the diagnosis and treatment of diffuse large B-cell lymphoma |
| |
| Li Tao,Zhou Liqiang. Progress in the diagnosis and treatment of diffuse large B-cell lymphoma[J]. Oncology Progress, 2006, 4(5): 384-390 |
| |
| Authors: | Li Tao Zhou Liqiang |
| |
| Abstract: | Diffuse large B-cell lymphoma (DLBCL) is the most common Non-Hodgkin's lymphoma in adults. DLBCL displays a striking heterogeneity at the clinical,genetic,and molecular levels. Commonly observed genetic abnormalities in DLBCL includes translocation of BCL6,BCL2,cMYC,and FAS(CD95) mutations and aberrant somatic hyper-mutation. Although CHOP can be curative for DLBCL,the complete remission(CR) rate remain 45%-55%. Intensified chemotherapy or autologous stem cell transplantation improves treatment outcomes only for some patients. The most striking and consistent improvement over CHOP chemotherapy in the treatment of DLBCL is the addition of anti-CD20 monoclonal antibody. |
| |
| Keywords: | diffuse large B-cell lymphoma diagnosis chemotherapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
